Strikingly, hemizygous deletion of Atg5 enhances melanoma growth (compared to Atg5+/+ or Atg5−/−), metastatic power and resistance to targeted therapy, such as BRAF inhibitor (Figure 1C) (65). This evidence concerns the gene BRAF and melanoma.